Literature DB >> 2872061

Effect of cirrhosis and renal failure on the kinetics of clotiazepam.

H R Ochs, D J Greenblatt, M Knüchel.   

Abstract

The kinetics of a single 5-mg oral dose of the thienodiazepine clotiazepam was evaluated in a series of patients with biopsy-proven cirrhosis, and in patients with renal insufficiency requiring maintenance hemodialysis, compared to healthy matched controls. Clotiazepam volume of distribution (Vz) was significantly smaller in cirrhotic patients than in controls (1.83 vs 2.57 l/kg), and total clearance was likewise reduced (2.15 vs 3.15 ml/min/kg). Elimination half-life was similar between groups (10.0 vs. 10.2 h). There were no significant differences between renal failure and control patients in clotiazepam Vz, oral clearance, or elimination half-life. Thus cirrhosis is associated with reduced clearance of clotiazepam, probably due to impairment of its microsomal oxidation. However clotiazepam disposition is not significantly altered in dialysis-dependent renal insufficiency patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872061     DOI: 10.1007/bf00614202

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Pharmacokinetics of diazepam in disordered liver function.

Authors:  P B Andreasen; J Hendel; G Greisen; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

3.  Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease.

Authors:  U Busch; M Molzahn; G Bozler; F W Koss
Journal:  Arzneimittelforschung       Date:  1981

4.  Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency.

Authors:  D J Greenblatt; T G Murray; P R Audet; A Locniskar; H H Koepke; B R Walker
Journal:  Nephron       Date:  1983       Impact factor: 2.847

5.  Importance of protein binding for the interpretation of serum or plasma drug concentrations.

Authors:  D J Greenblatt; E M Sellers; J Koch-Weser
Journal:  J Clin Pharmacol       Date:  1982 May-Jun       Impact factor: 3.126

6.  The pharmacokinetics of midazolam in chronic renal failure patients.

Authors:  H R Vinik; J G Reves; D J Greenblatt; D R Abernethy; L R Smith
Journal:  Anesthesiology       Date:  1983-11       Impact factor: 7.892

7.  Alprazolam pharmacokinetics in alcoholic liver disease.

Authors:  R P Juhl; D H Van Thiel; L W Dittert; R B Smith
Journal:  J Clin Pharmacol       Date:  1984 Feb-Mar       Impact factor: 3.126

8.  Disposition of oxazepam in patients on maintenance hemodialysis.

Authors:  H R Ochs; D J Greenblatt; U Klehr
Journal:  Klin Wochenschr       Date:  1984-08-16

9.  Diazepam kinetics in patients with renal insufficiency or hyperthyroidism.

Authors:  H R Ochs; D J Greenblatt; H J Kaschell; U Klehr; M Divoll; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

10.  Renal disease, age, and oxazepam kinetics.

Authors:  T G Murray; S T Chiang; H H Koepke; B R Walker
Journal:  Clin Pharmacol Ther       Date:  1981-12       Impact factor: 6.875

View more
  2 in total

Review 1.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 2.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.